Targeting CXCR6 suppresses granuloma formation and pulmonary fibrosis through inhibiting Th17 responses in sarcoidosis
International Immunopharmacology · 2026-08 · 182 · 116845
DOI: 10.1016/j.intimp.2026.116845 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026-08. Verfasst von Yueyin Han und 13 weiteren Autor:innen. Beteiligte Einrichtung: China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing…. Hauptthemen laut MEDLINE: Receptors, CXCR6, Th17 Cells, Pulmonary Fibrosis, Granuloma. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Key Technologies Research and Development Program, Beijing Nova Program, National Natural Science Foundation of China.
Abstract (Originalsprache)
Sarcoidosis is a systemic granulomatous disease that often affects the lungs, lymph nodes, and skin. The pathological hallmark of sarcoidosis is the formation of epithelioid, non-necrotizing granulomas, with CD4+ T-helper (Th) type 1 (Th1), Th17, and Th17.1 cells scattering throughout the granuloma. The CXCL16-CXCR6 axis plays a crucial role in the development of inflammatory diseases. However, the precise role of CXCR6+ CD4+ T cells in sarcoidosis pathogenesis and their therapeutic potential remain unclear. In this study, we confirmed the enrichment of CXCR6+ CD4+ T cells in the lesional tissue of sarcoidosis patients and Propionibacterium acnes-induced sarcoidosis-like model mice. Flow cytometric analysis and single-cell RNA sequencing revealed that CXCR6+ CD4+ T cells exhibited a Th17/Th17.1 phenotype and displayed pro-inflammatory characteristics. By performing cell-cell communication analysis and validating the findings with flow cytometry and CXCL16-blockade experiments, we demonstrated an active crosstalk between CXCR6+ CD4+ T cells and CXCL16+ macrophages in mice. Furthermore, treating mice with an anti-CXCR6 monoclonal antibody effectively reduced the mRNA levels of pro-inflammatory genes, including Nos2, Cxcl9, Cxcl10, Il17a, Tnf, and Ifng. In addition, anti-CXCR6 treatment reduced the abundance of Th17 and Th17.1 cells, which was associated with inhibition of downstream mTORC1 signaling. Finally, anti-CXCR6 treatment suppressed granuloma formation and attenuated collagen deposition in the lungs. Taken together, our findings highlight CXCR6 as a promising therapeutic target for inhibiting granuloma formation and pulmonary fibrosis in sarcoidosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China; National Center for Respiratory Medicine; State Key Laborator…
- National Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Chinese Academy of…
- Department of Pulmonary and Critical Care Medicine, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing, China.
- Department of Physiology, State Key Laboratory of Common Mechanism Research for Major Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Basic Medical Sciences and School of Basic Medicine, Chinese Academy of Me…
- Center for Interstitial and Rare Lung Diseases, Pneumology Department, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany.
Förderung
- Key Technologies Research and Development Program
- Beijing Nova Program
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Han, Y., Liu, M., Xu, W., Li, Z., Jiang, D., Geng, J., Gao, S., Li, S., Xie, B., Zhu, L., Zhang, H., Costabel, U., Dai, H., & Wang, C. (2026). Targeting CXCR6 suppresses granuloma formation and pulmonary fibrosis through inhibiting Th17 responses in sarcoidosis. International Immunopharmacology, 182, 116845. https://doi.org/10.1016/j.intimp.2026.116845
Vancouver
Han Y, Liu M, Xu W, Li Z, Jiang D, Geng J, et al. Targeting CXCR6 suppresses granuloma formation and pulmonary fibrosis through inhibiting Th17 responses in sarcoidosis. International Immunopharmacology. 2026;182:116845. doi:10.1016/j.intimp.2026.116845
BibTeX
@article{Han2026,
author = {Han, Yueyin and Liu, Mengyuan and Xu, Wenxiu and Li, Zhen and Jiang, Dingyuan and Geng, Jing and Gao, Shuwei and Li, Shifeng and Xie, Bingbing and Zhu, Lili and Zhang, Hongbing and Costabel, Ulrich and Dai, Huaping and Wang, Chen},
title = {Targeting CXCR6 suppresses granuloma formation and pulmonary fibrosis through inhibiting Th17 responses in sarcoidosis},
journal = {International Immunopharmacology},
year = {2026},
volume = {182},
pages = {116845},
doi = {10.1016/j.intimp.2026.116845}
}
EUVIMED